In the BioHarmony Drug Report Database

"Preview" Icon

Emicizumab

Hemlibra (emicizumab) is an antibody pharmaceutical. Emicizumab was first approved as Hemlibra on 2017-11-16. It is used to treat hemophilia a in the USA. It has been approved in Europe to treat hemophilia a. It is known to target coagulation factor IX and coagulation factor X.

 

Trade Name

 

Hemlibra
 

Common Name

 

emicizumab
 

ChEMBL ID

 

CHEMBL3833393
 

Indication

 

hemophilia a
 

Drug Class

 

Monoclonal antibodies: humanized, cardiovascular indications

Image (chem structure or protein)

Emicizumab structure rendering